Research Analysts Set Expectations for MDGL FY2028 Earnings

Key Points

• Leerink Partners has lowered its FY2028 earnings per share estimate for Madrigal Pharmaceuticals from $29.38 to $28.37, while the consensus forecast for the year stands at a loss of $23.47 per share.
• Madrigal Pharmaceuticals reported a quarterly earnings EPS of ($1.90), exceeding expectations by $1.58, with a significant revenue increase of 1357.5% year-over-year.
• Despite a slight drop in share price, Madrigal has received multiple buy ratings from various analysts, maintaining a consensus rating of "Moderate Buy" and a price target averaging around $421.63.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at Leerink Partnrs lowered their FY2028 EPS estimates for Madrigal Pharmaceuticals in a report released on Tuesday, August 5th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings of $28.37 per share for the year, down from their previous estimate of $29.38. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. Leerink Partnrs also issued estimates for Madrigal Pharmaceuticals' FY2029 earnings at $50.04 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.48) by $1.58. The business had revenue of $212.80 million for the quarter, compared to analysts' expectations of $158.94 million. Madrigal Pharmaceuticals had a negative return on equity of 38.38% and a negative net margin of 54.68%. The company's quarterly revenue was up 1357.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($7.10) EPS.

Several other research analysts also recently weighed in on the stock. Wall Street Zen raised shares of Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th. UBS Group lifted their price objective on shares of Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. JMP Securities reiterated a "market outperform" rating and set a $443.00 price target on shares of Madrigal Pharmaceuticals in a report on Thursday, April 24th. B. Riley reiterated a "buy" rating and set a $460.00 price target (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a report on Friday, May 2nd. Finally, Canaccord Genuity Group lifted their price target on Madrigal Pharmaceuticals from $420.00 to $428.00 and gave the company a "buy" rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $430.43.

Madrigal Pharmaceuticals Trading Up 1.0%

MDGL traded up $3.44 during trading on Thursday, reaching $345.73. The company had a trading volume of 353,096 shares, compared to its average volume of 441,104. The firm's 50-day simple moving average is $301.66 and its 200 day simple moving average is $313.02. The company has a market cap of $7.68 billion, a price-to-earnings ratio of -26.91 and a beta of -1.02. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.58 and a current ratio of 5.11. Madrigal Pharmaceuticals has a 12-month low of $200.63 and a 12-month high of $377.46.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Several large investors have recently made changes to their positions in MDGL. Rhumbline Advisers grew its position in Madrigal Pharmaceuticals by 7.9% in the first quarter. Rhumbline Advisers now owns 26,364 shares of the biopharmaceutical company's stock worth $8,733,000 after acquiring an additional 1,924 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Madrigal Pharmaceuticals by 131.4% in the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 67 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Madrigal Pharmaceuticals by 340.1% in the fourth quarter. Franklin Resources Inc. now owns 6,087 shares of the biopharmaceutical company's stock worth $1,878,000 after purchasing an additional 4,704 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Madrigal Pharmaceuticals in the fourth quarter worth $16,615,000. Finally, XTX Topco Ltd bought a new stake in Madrigal Pharmaceuticals in the first quarter worth $392,000. Institutional investors own 98.50% of the company's stock.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, Director Rebecca Taub sold 26,444 shares of the business's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $353.47, for a total value of $9,347,160.68. Following the transaction, the director owned 461,044 shares in the company, valued at $162,965,222.68. The trade was a 5.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Paul A. Friedman sold 26,176 shares of the business's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $353.47, for a total value of $9,252,430.72. Following the completion of the transaction, the director owned 187,164 shares in the company, valued at $66,156,859.08. This trade represents a 12.27% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,377 shares of company stock worth $21,316,969. 21.50% of the stock is currently owned by corporate insiders.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.